Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Vectivbio AG maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions for this portfolio. Both of these actions are being handled by 1 distinct examiner and are located within 1 distinct art unit. This indicates a high level of concentration for the company's active patent prosecution.
The busiest examiner for Vectivbio AG is KATAKAM, SUDHAKAR, who is responsible for 2 busiest examiner pending actions. For a practitioner, this concentration simplifies the prosecution landscape, as all active matters are under the review of a single individual in a single art unit. However, it also means that the portfolio's immediate progress is entirely dependent on the decisions of this one examiner. The lack of multiple distinct examiners or art units suggests that the pending applications are technically similar or closely related. A consistent strategy tailored to this specific examiner's requirements is essential for resolving the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 2 | 74.7% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18619647 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | KATAKAM, SUDHAKAR | — |
| 18274622 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18619647 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | KATAKAM, SUDHAKAR | — | §103DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18274622 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial